Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S.

Mol Ther. 2009 Oct;17(10):1779-87. doi: 10.1038/mt.2009.133. Epub 2009 Jun 16.

2.

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.

Knutson KL, Disis ML.

Clin Breast Cancer. 2001 Apr;2(1):73-9. Review.

PMID:
11899386
3.

Potential of human γδ T cells for immunotherapy of osteosarcoma.

Li Z.

Mol Biol Rep. 2013 Jan;40(1):427-37. doi: 10.1007/s11033-012-2077-y. Epub 2012 Oct 14. Review.

PMID:
23065272
4.

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.

Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M.

Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Review.

PMID:
25901860
5.

Genetically modified T-cell therapy for osteosarcoma.

DeRenzo C, Gottschalk S.

Adv Exp Med Biol. 2014;804:323-40. doi: 10.1007/978-3-319-04843-7_18. Review.

6.

Genetic Modification of T Cells.

Morgan RA, Boyerinas B.

Biomedicines. 2016 Apr 20;4(2). pii: E9. doi: 10.3390/biomedicines4020009. Review.

7.

T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Wang Z, Li B, Ren Y, Ye Z.

Front Immunol. 2016 Sep 14;7:353. doi: 10.3389/fimmu.2016.00353. eCollection 2016. Review.

Supplemental Content

Support Center